Table 1.
Clinical baseline characteristics of the two subgroups
| Characteristics |
Subgroup 1 Sorafenib (n = 147) |
Subgroup 2 Sorafenib + SIRT (n = 150) |
|---|---|---|
| Age, years, median (range) | 68 (46–85) | 67 (50–84) |
| Male/female (%) | 86.4/13.6 | 88.0/12.0 |
| BCLC stage (%) | ||
| A | 1.3 | 3.3 |
| B | 32.0 | 31.3 |
| C | 66.7 | 65.4 |
| Aetiology, n (%) | ||
| AIH | 1 (0.7) | 0 (0) |
| Alcohol | 54 (36.7) | 59 (39.3) |
| Alcohol + viral | 4 (2.7) | 10 (6.7) |
| HBV | 13 (8.8) | 11 (7.3) |
| HCV | 29 (19.7) | 29 (19.3) |
| HC | 1 (0.7) | 6 (4.0) |
| NAFLD | 10 (6.8) | 6 (4.0) |
| NASH | 8 (5.4) | 13 (8.7) |
| NS | 4 (2.7) | 3 (2.0) |
| Cryptogenic | 23 (15.6) | 13 (8.7) |
| NAT | 0 | 1 (0.7) |
| ECOG (%) | 0: 73.4 | 0: 69.3 |
| 1: 25.9 | 1: 28.7 | |
| 2: 0.7 | C: 2.0 |
Abbreviations: AIH, autoimmune hepatitis; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HC, haemochromatosis; HCV, hepatitis C virus; NAFLD, non‐alcoholic fatty liver disease; NASH, non‐alcoholic steatohepatitis; NAT, non‐alcoholic toxic; NS, not specified; SIRT, selective internal radiation therapy.